Table 1

Baseline characteristics of patients with AS, uSpA, PsA and GP comparators at start of follow-up

AS (n=6448)uSpA (n=5190)PsA (n=16 063)GP (n=266 435)
Sex
  Male4390 (68.1)2325 (44.8)7217 (44.9)131 807 (49.5)
  Female2058 (31.9)2865 (55.2)8846 (55.1)134 628 (50.5)
Age (years)
  Mean (SD); men50.3 (13.9)44.2 (13.4)52.6 (13.4)53.5 (15.7)
  Mean (SD); women49.5 (13.8)45.1 (13.1)53.7 (14.1)53.4 (16.0)
  18–29 years488 (7.6)691 (13.3)761 (4.7)18 465 (6.9)
  30–39 years1120 (17.4)1255 (24.2)2047 (12.7)36 805 (13.8)
  40–49 years1452 (22.5)1406 (27.1)3368 (21.0)52 122 (19.6)
  50–59 years1670 (25.9)1085 (20.9)4385 (27.3)63 559 (23.9)
  60–69 years1209 (18.8)583 (11.2)3638 (22.6)52 626 (19.8)
  70–79 years414 (6.4)132 (2.5)1422 (8.9)27 259 (10.2)
 ≥80 years95 (1.5)38 (0.7)442 (2.8)15 599 (5.9)
Start of follow-up
  2006–20074938 (76.6)3725 (71.8)11 926 (74.2)266 234 (99.9)
  2008–20101510 (23.4)1465 (28.2)4137 (25.8)201 (0.1)
Level of education
 ≤9 years1423 (22.1)804 (15.5)4039 (25.1)68 776 (25.8)
 10–12 years3096 (48.0)2566 (49.4)7983 (49.7)119 681 (44.9)
 >12 years1858 (28.8)1789 (34.5)3931 (24.5)74 587 (28.0)
 Missing71 (1.1)31 (0.6)110 (0.7)3391 (1.3)
SpA-related comorbidities*
  Anterior uveitis1342 (20.8)771 (14.9)252 (1.6)1156 (0.4)
  Inflammatory bowel disease514 (8.0)269 (5.2)346 (2.2)2565 (1.0)
  Psoriasis145 (2.2)162 (3.1)15 873 (98.8)2190 (0.8)
SpA-related current medications†
  Any DMARD1599 (24.8)1579 (30.4)6659 (41.5)2542 (1.0)
  TNF inhibitors545 (8.5)279 (5.4)758 (4.7)268 (0.1)
  Methotrexate494 (7.7)609 (11.7)5094 (31.7)1104 (0.4)
  Sulfasalazin798 (12.4)877 (16.9)1396 (8.7)493 (0.2)
  NSAIDs3543 (54.9)2804 (54.0)7801 (48.6)28 467 (10.7)
  Prednisone659 (10.2)778 (15.0)2133 (13.3)4234 (1.6)
Other comorbidities*
  Ischaemic heart disease468 (7.3)182 (3.5)1091 (6.8)14 849 (5.6)
  Heart failure203 (3.1)53 (1.0)386 (2.4)5225 (2.0)
  Cerebrovascular disease160 (2.5)79 (1.5)454 (2.8)7763 (2.9)
  AV block II–III56 (0.9)22 (0.4)48 (0.3)710 (0.3)
  AF264 (4.1)87 (1.7)513 (3.2)7430 (2.8)
  PM66 (1.0)28 (0.5)73 (0.5)1221 (0.5)
  Aortic regurgitation73 (1.1)20 (0.4)62 (0.4)676 (0.3)
  Aortic valve surgery41 (0.6)9 (0.2)41 (0.3)573 (0.2)
Dispensed prescriptions†
  Oral antidiabetics or insulin274 (4.2)123 (2.4)1077 (6.7)11 372 (4.3)
  Antihypertensive1794 (27.8)846 (16.3)4853 (30.2)59 053 (22.2)
  Statins657 (10.2)307 (5.9)1871 (11.6)23 180 (8.7)
  Aspirin557 (8.6)230 (4.4)1519 (9.5)23 655 (8.9)
  Warfarin174 (2.7)52 (1.0)277 (1.7)4328 (1.6)
  • Age is given in mean (SD). All other data are presented in number (%). Parts of the baseline characteristics in Table 1 have previously been published.31

  • *Prevalent comorbidity at baseline, defined by identification of specified International Classification of Diseases codes or surgical procedure codes in the National Patient Register prior to start of follow-up.

  • †Dispensed prescription in Prescribed Drug Register or intravenous biologic DMARD in Swedish Rheumatology Quality register within 6 months prior to start of follow-up.

  • AF, atrial fibrillation/flutter; AS, ankylosing spondylitis; AV, atrioventricular; DMARD, disease-modifying antirheumatic drug; GP, general population; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PM, pacemaker implantation; TNF, tumour necrosis factor; uSpA, undifferentiated spondyloarthritis.